Full text
Earnings transcript
Read the complete earnings call transcript.
OMER
Omeros Corporation
$9.97
0.12
(1.22%)
| Exchange: | NASDAQ |
| Market Cap: | 721.582M |
| Shares Outstanding: | 57.177M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Gregory A. Demopulos | |||||
| Full Time Employees: | 202 | |||||
| Address: |
| |||||
| Website: | https://www.omeros.com |
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company’s therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros’s preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| EBITDA | -143,156 | -157,004 | -121,832 |
| Operating Income | -164,530 | -169,258 | -122,796 |
| Net Income | -117,813 | -156,815 | -3,350 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 378,269 | 277,079 | 325,632 |
| Total Liabilities | 403,252 | 459,688 | 446,863 |
| Total Stockholders Equity | -24,983 | -182,609 | -121,231 |
| Total Debt | 361,584 | 207,020 | 13,545 |
| Cash and Cash Equivalents | 7,105 | 3,400 | 9,660 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 74,726 | -148,803 | -116,094 |
| Capital Expenditure | -426 | -165 | -65 |
| Free Cash Flow | 74,300 | -148,968 | -116,159 |
| Net Income | -117,813 | -156,815 | -3,350 |
| Net Change in Cash | -3,904 | -3,705 | 6,260 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 461,953.499 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 561,138.249 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 501,900 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 160,567.762 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 206,578.998 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 179,098.769 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 2.820 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 3.250 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 2.530 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Performance Metrics: OMER demonstrates consistent revenue growth as reflected in the Income Statements, with positive trends in gross profit and operating income over recent periods. This indicates operational efficiency and a strong core business model within the industry.
- Healthy Cash Flow Position: Data from the Cash Flow Statements highlights positive net cash provided by operating activities and a robust free cash flow yield (as per Key Metrics). This financial stability supports reinvestment and debt management.
- Competitive Industry Positioning: Performance metrics show OMER outperforming industry averages in key areas such as perf1y and perf5y, suggesting a competitive edge within its sector (as per Industry and Sector data).
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about OMER valuation
Is Omeros Corporation (OMER) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Omeros Corporation (OMER) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is OMER a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OMER trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is OMER’s P/E ratio?
You can see OMER’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for OMER?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is OMER a good long-term investment?
Whether OMER fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
OMER
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.22
Trading Metrics:
| Open: | 9.86 | Previous Close: | 9.85 | |
| Day Low: | 9.55 | Day High: | 10.04 | |
| Year Low: | 2.95 | Year High: | 17.65 | |
| Price Avg 50: | 12.4 | Price Avg 200: | 9.89 | |
| Volume: | 1.544M | Average Volume: | 1.315M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeOMER full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Omeros Corporation, ticker OMER, a biopharmaceutical company that’s been making waves in the healthcare space. If you’re looking to understand whether this stock is a potential gem for your portfolio, stick around because we’re covering everything from financials to recent performance, valuation, and more. Let’s get started! Alright, first things first, let’s set the stage. Omeros is a company that’s been around since 1994,…
